The custom antibody services market size is projected to reach US$ 1,216.35 million by 2031 from US$ 590.33 million in 2023. The market is expected to register a CAGR of 9.5% during 2023–2031. Technological advancements utilizing recombinant antibodies are likely to bring new trends in the custom antibody services market in the coming years.
The factors driving the custom antibody services market include government funding and support for research in antibody-related fields, coupled with the expansion into translational medicine. The growing emphasis on personalized medicine is fueling the demand for custom antibody solutions. Technological advancements using recombinant antibodies are boosting the growth of the custom antibody services market. Increasing demand for customized diagnostic and therapeutic treatments has boosted players to invest in product development and expansion strategies.
Custom antibodies are essential to personalized therapies, as they can be designed to target specific molecular markers that are unique to an individual patient's disease. The custom antibody services market in the UK is anticipated to grow substantially owing to the growing prevalence of chronic diseases such as cancer and cardiovascular diseases. According to Cancer Research UK, ~360,000 people are diagnosed with cancer annually in the nation. The annual count of cancer diagnoses is projected to reach 500,000 by 2040. Antibodies have been demonstrated to prolong overall disease-free survival and delay disease progression in several cases. Custom antibody services are needed for the development of more targeted therapeutic antibody treatments to treat cancer more effectively.
Custom antibodies can help target specific tumor markers, improving the effectiveness and reducing side effects of cancer treatment. In September 2023, AMSBIO supplied a custom monoclonal antibody to researchers at the Technical University Dortmund, Germany, to unravel the role of EDI3 (a glycerophosphodiesterase enzyme involved in choline metabolism) in breast cancer development, its regulation by HER2 signaling, and its potential as a therapeutic target.
The Food and Drug Administration (FDA) approves biosimilar products and provides the scientific and regulatory advice needed to introduce safe and effective biosimilars to the market. The approval of biosimilar products can improve patient care by increasing the number of medication options at potentially lower costs.
A few recent approvals of biosimilar products are mentioned below:
Alymsys (bevacizumab-maly)
April 2022
Avastin (bevacizumab)
Cimerli (ranibizumab-eqrn)
August 2022
Lucentis (ranibizumab)
Fylnetra (pegfilgrastim-pbbk)
May 2022
Neulasta (pegfilgrastim)
Stimufend (pegfilgrastim-fpgk)
September 2022
Neulasta (pegfilgrastim)
Vegzelma (bevacizumab-adcd)
September 2022
Avastin (bevacizumab)
Idacio (adalimumab-aacf)
December 2022
Humira (adalimumab)
Biosimilars can reduce treatment costs and improve patient access to biologic therapies. In recent years, a vast range of biosimilars have been approved by the FDA. According to ScienceDirect.com, biosimilars can retain costs and expand the availability of monoclonal antibodies. Furthermore, in Europe, five rituximab biosimilars, six trastuzumab biosimilars, and eight bevacizumab biosimilars are available as anti-cancer drugs. Thus, the rising approvals of biosimilars fuel the growth of the custom antibody services market.
Governments of various emerging countries are launching several research and development initiatives focusing on genomics and proteomic methods. For instance, The Proteomics Society, an organization in India, aims to promote the field of proteomics and the professional interests of the Proteomics Community in the country. The organization also helps facilitate research collaborations and workshops, driving the demand for custom antibody products. The Single Cell Proteomics Initiative of the US was established in 2022 from international laboratories that were proficient in performing Single-Cell Proteomics (SCP) workflows. The goal of the Single-Cell Initiative under the Biology and Disease-Driven Human Proteome Project unveiled in 2022 fostered the development and application of SCP methods and technologies. This initiative aims to accelerate knowledge exchange and resources within established and newly interested SCP researchers. The initiative organizes webinars, workshops, and symposia to showcase the modern advances and challenges in SCP, which are complemented by generating dedicated resources. Therefore, the rise in research and development initiatives by governments of various developing economies is expected to create lucrative opportunities for the growth of the custom antibody services market during the forecast period.
Key segments that contributed to the derivation of the custom antibody services market analysis are product type, service type, application, source, disease indication, and end user.
The geographic scope of the custom antibody services market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.
North America held a significant share of the market in 2023. The growth of the market is driven by rising collaborations between government entities and market players to encourage the utilization of custom antibodies in clinical diagnostics. In addition, the acceptance and adoption of advanced technological solutions, increasing investments in drug discovery and development, extensive government support for clinical research, and an upsurge in research activities in clinical diagnostics are projected to accelerate the growth of the custom antibody services market in the region.
The growing number of cancer and genomic research programs run by universities in the US and Canada, increasing focus on developing antibody-based therapeutics, the presence of a large number of global players, and the burgeoning demand for high-quality research tools for data reproducibility are a few of the other factors contributing to the expansion of the market across North America.
The regional trends and factors influencing the Custom Antibody Services Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Custom Antibody Services Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
| Report Attribute | Details |
|---|---|
| Market size in 2023 | US$ 590.33 Million |
| Market Size by 2031 | US$ 1,216.35 Million |
| Global CAGR (2023 - 2031) | 9.5% |
| Historical Data | 2021-2022 |
| Forecast period | 2024-2031 |
| Segments Covered |
By Product Type
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The Custom Antibody Services Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Custom Antibody Services Market are:
Disclaimer: The companies listed above are not ranked in any particular order.
The custom antibody services market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the custom antibody services market are listed below:
The “Custom Antibody Services Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:
The List of Companies - Custom Antibody Services Market
Custom antibodies are essential to personalized therapies, as they can be designed to target specific molecular markers that are unique to an individual patient's disease. Custom antibody services are specialized services provided by companies to develop antibodies tailored to specific needs for research, diagnostic, and therapeutic purposes. These services include the entire process, from antigen design, immunization, and antibody production to purification and validation.
The factors driving the growth of the custom antibody services market include the increasing prevalence of chronic diseases and rising approvals of biosimilars. However, the high costs and complexities associated with antibody production using transgenic animals hampers the growth of the custom antibody services market.
The custom antibody services market majorly consists of the players, including Thermo Fisher Scientific Inc.; Sino Biological Inc.; GenScript Biotech Corporation; Biochain Incorporated; R&D Systems, Inc.; Kaneka Eurogentec S.A.; Fortis Life Sciences; Precision Antibody; Biocytogen Pharmaceuticals Beijing Co Ltd; and Abgenex.
The custom antibody services market was valued at US$ 590.33 million in 2023.
The custom antibody services market is expected to be valued at US$ 1,216.35 million by 2031.
The custom antibody services market, by product type, is segmented into monoclonal, polyclonal hybridoma, recombinant antibody, and others. In 2023, the monoclonal segment held the largest share of the market.